SMA区域存在大片段缺失的脊髓型肌萎缩症3型患者：1例报告

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by degeneration and loss of anterior horn cells in the spinal cord and brain stem nuclei,leading to progressive limb and trunk paralysis and muscular atrophy.Depending on the age of onset and maximum muscular function achieved,SMA is recognized as SMA1,SMA2,SMA3 or SMA4,and most patients have a deletion or truncation of the survival motor neuron 1 (SMN1) gene.In this report,we present a patient with a mild SMA phenotype,SMA3,and define his genetic abnormality.Tetra-primer amplification refractory mutation system PCR combined with restriction fragment length polymorphism analysis and array comparative genomic hybridization were used to determine the genetic variations in this patient.A 500 kb deletion in chromosome 5q13.2,including homozygous deletion of neuronal apoptosis inhibitory protein,and heterozygous deletion of occludin and B-double prime 1 was identified.This SMA region deletion did not involve SMN,indicating that SMN was likely to function normally.The phenotype was dependent of the large deletion and neuronal apoptosis inhibitory protein,occludin and B-double prime 1 may be candidate genes for SMA3.

Large deletions within the spinal muscular atrophy gene region in a patient with spinal muscular atrophy type 3

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by degeneration and loss of anterior horn cells in the spinal cord and brain stem nuclei, leading to progressive limb and trunk paralysis and muscular atrophy. Depending on the age of onset and maximum muscular function achieved, SMA is recognized as SMA1, SMA2, SMA3 or SMA4, and most patients have a deletion or truncation of the survival motor neuron 1 (SMN1) gene. In this report, we present a patient with a mild SMA phenotype, SMA3, and define his genetic abnormality. Tetra-primer amplification refractory mutation system PCR combined with restriction fragment length polymorphism analysis and array comparative genomic hybridization were used to determine the genetic variations in this patient. A 500 kb deletion in chromosome 5q13.2, including homozygous deletion of neuronal apoptosis inhibitory protein, and heterozygous deletion of occludin and B-double prime 1 was identified. This SMA region deletion did not involve SMN, indicating that SMN was likely to function normally. The phenotype was dependent of the large deletion and neuronal apoptosis inhibitory protein, occludin and B-double prime 1 may be candidate genes for SMA3.